Company profile
Korro Bio, Inc.
NASDAQ: KRRO · Healthcare · Biotechnology
#683 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
41DFH 30DQ 46GM 60SS 50
v0.1 · 65/100 weight · provisional
↑ revenue growth (YoY), market scale · ↓ return on equity, operating margin
Methodology →Revenue TTM
$2.4M
Rev growth YoY (TTM)
-62.1%
Net income (FY)
-$117.3M
Employees
58
as of 2026-08-14
Market cap
$132.3M
as of 2026-08-14
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$6.4M$6.4M2025
Net income-$117.3M-$117.3M2025
Operating income-$121.9M-$121.9M2025
Total assets$113.5M$113.5M2025
Liabilities$62.1M$62.1M2025
Equity$51.4M$51.4M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY24
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Korro Bio, Inc.’s revenue?
Korro Bio, Inc. booked $6.4M in FY2025 revenue, growing 181% year over year — faster than most Healthcare companies we track, at a -1834.5% net margin.
Peers · Healthcare
GlobeImmune, Inc.——Kyntra Bio, Inc.60CViveve Medical, Inc.——HTG Molecular Diagnostics, Inc.——Jack Nathan Medical Corp.——Scorpius Holdings, Inc.——Neighbors
Middlesex →Key facts
CEORam Aiyar
SectorHealthcare
IndustryBiotechnology
HeadquartersCambridge, MA
ExchangeNASDAQ: KRRO
Employees58
IPO date2019-10-03
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.